Posted by Michael Wonder on 29 Sep 2023
Odronextamab BLA for treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma accepted for FDA priority review
29 September 2023 - If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common sub-types of non-Hodgkin lymphoma.
Regeneron Pharmaceuticals today announced that the US FDA has accepted for priority review the biologics license application for odronextamab to treat adult patients with relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma, who have progressed after at least two prior systemic therapies.
